Abstract: A process of purifying a Growth Factor Protein in a purification sequence employing chromatography characterized in that at least one chromatography is performed using a multimodal resin the Growth Factor Protein binds to the multimodal resin at a pH between 4 to 6.2, and the Growth Factor Protein is eluting at a pH >6.3, and the elution of Growth Factor Protein is improved by addition of arginine and/or NaCl to the eluting buffer. The multimodal resin step is followed by a yeast derived affinity ligand resin step, which results of a purity of the product >90%.
Type:
Application
Filed:
September 2, 2016
Publication date:
February 23, 2017
Applicant:
OCTAPHARMA AG
Inventors:
Gustav Gilljam, Stefan Winge, Maya Tiemeyer
Abstract: The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.
Abstract: A process for manufacturing of a Factor VIII product having a ratio of FVIII:C/FVIII:Ag of at least 0.7 in the Factor VIII product by using chromatography wherein at least one chromatographic step is performed by means of employing; An affinity chromatography resin having an affinity for specifically binding of Factor VIII which is effected by an affinity ligand which is immobilised on the affinity chromatography resin, said affinity ligand is a 13 kD yeast derived Fab antibody fragment directed to the Factor VIII molecule. An anionic chromatography resin. A size exclusion resin. A Factor VIII product obtainable according to the process with a monomer content of >98% for treatment of haemophilia and avoiding formation of inhibitors.
Type:
Application
Filed:
January 20, 2015
Publication date:
November 24, 2016
Applicant:
OCTAPHARMA AG
Inventors:
Stefan Winge, Marina Dadaian, Erica Johansson, Birte Fuchs
Abstract: A process of purifying the Growth Factor Protein G-CSF (Granulocyte Colony Stimulating Factor) in a purification sequence employing chromatography, comprising binding the G-CSF to Capto MMC™, which is a multimodal resin that comprises a negatively charged 2-(benzoylamino) butanoic acid ligand, at a pH from 4 to 6.2; and eluting the G-CSF at a pH greater than 6.3.
Type:
Grant
Filed:
March 30, 2011
Date of Patent:
September 27, 2016
Assignee:
OCTAPHARMA AG
Inventors:
Gustav Gilljam, Stefan Winge, Maya Tiemeyer
Abstract: The present invention relates to a method or process for the manufacture of a virus and prion save native fibrinogen concentrate of high purity and low amounts of fibrinopeptide A and fibronectin.
Type:
Application
Filed:
May 25, 2016
Publication date:
September 15, 2016
Applicant:
OCTAPHARMA AG
Inventors:
Petra Schulz, Rainer Pape, Werner Gehringer
Abstract: A method for stabilising a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa.
Abstract: The present invention provides a method for increasing the yield of a protein produced by cultivating eukaryotic cells and adding an ionic substance to the culture medium prior to harvest of the protein. Suitable ionic substances are the salts of the Hofmeister series, amino acids and peptone.
Abstract: The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.
Abstract: The present invention relates to a method or process for the manufacture of a virus and prion save native fibrinogen concentrate of high purity and low amounts of fibrinopeptide A and fibronectin.
Type:
Grant
Filed:
September 20, 2011
Date of Patent:
June 21, 2016
Assignee:
OCTAPHARMA AG
Inventors:
Petra Schulz, Rainer Pape, Werner Gehringer
Abstract: A process for isolation and purification of a target protein by chromatography wherein the chromatography removes or depletes prions (PrPSC), comprising the steps of contacting a potentially PrPSC contaminated sample comprising a target protein with a multimodal chromatographic material; setting buffer conditions so that the target protein is bound to the multimodal chromatographic material and whereas PrPSC is not binding to the multimodal chromatographic material; followed by elution of the target protein. a process for isolation and purification of a target protein free of prion protein (prpSC).
Type:
Grant
Filed:
August 25, 2008
Date of Patent:
March 29, 2016
Assignee:
OCTAPHARMA AG
Inventors:
Gustav Gilljam, Mats Jernberg, Stefan Winge, Andrea Neisser-Svae
Abstract: A non-hemolytic acidic composition comprising an immunoglobulin selected from immunoglobulin A, immunoglobulin G or immunoglobulin M at a pH value in the range of 4.65 to 5.7 comprising one or more excipients selected from amino acids, sugars and sugar alcohols in a concentration range of 100-350 mmol/l, in particular 200-350 mmol/l, characterized in that it displays an optical density (OD) in the range of 0.14 to ?0.1 when the OD is determined in a spectrophotometer at 414 nm at a film thickness of 0.825 mm; and its use in an assay for determination of the hemolytic potential of intravenously applied pharmaceuticals and compositions and preparations displaying a reduced potential of hemolysis when being applied intravenously.
Type:
Application
Filed:
September 26, 2013
Publication date:
September 10, 2015
Applicant:
OCTAPHARMA AG
Inventors:
Andrea Heger, Tor-Einar Svae, Juergen Roemisch, Alfred Zoechling
Abstract: A recombinant human factor VIII or IX protein having a human glycosylation pattern but the protein is devoid of N-glycolylneuraminic acid and/or the carbohydrate group Gal?-3Gal.
Type:
Grant
Filed:
August 21, 2009
Date of Patent:
September 1, 2015
Assignee:
Octapharma AG
Inventors:
Helena Sandberg, Peter Stenlund, Carola Schröder, Elisabeth Casademunt, Maya Tiemeyer
Abstract: A method of increasing productivity, in particularly cell-specific productivity, of recombinant factor VIII (rFVIII) produced in a eukaryotic cell suspension during culturing of the eucaryotic cell suspension in a culturing medium containing not more than 500 ?M CaCl2, at least a non-ionic detergent and other nutrient components needed for the cells to grow and produce rFVIII, the cell suspension is cultured under conditions inducing a shear stress mechanically to the eucaryotic cell suspension by adding a power density of at least 3 W/m3.
Abstract: A method for determining the likelihood of response of an individual, suffering from a disease, towards immunoglobulin therapy has the steps of providing a sample containing B- and T-lymphocytes, natural killer cells, invariant T-cells and monocytes of the individual; genotyping of at least one of the polynucleotides of an ADAMTS9-Intron; a KLHDC8A-Intron or of a flanking region of the CD14 gene, and awarding the value of 1 for the homozygous Single Nucleotide Polymorphism combinations, which suggests that the blood sample stems from a person which will not respond to immunoglobulin treatment, while awarding the value of 0 for SNP not meeting that criteria, which suggests that the blood sample stems from a person which will respond to immunoglobulin treatment.
Type:
Application
Filed:
June 6, 2012
Publication date:
July 30, 2015
Applicant:
OCTAPHARMA AG
Inventors:
Stefan Meuer, Thomas Geise, Christian Jacobi, Stefan Haag, Juergen Roemisch
Abstract: A process for manufacturing of a composition containing a purified factor for supporting wound healing selected from the group consisting of Hepatocyte Growth Factor (HGF) platelet derived growth factor (PDGF), Epidermal growth factor (EGF), transforming growth factor alfa (TGF-?), Transforming growth factor beta (TGF-?), insulin like growth factor (IGF-I) and Fibroblast growth factor (FGF) from sources, such as blood, containing the factor for supporting wound healing, wherein the manufacturing process comprises purification steps which are performed in the presence of antithrombin III (AT-III).
Type:
Grant
Filed:
January 25, 2007
Date of Patent:
February 24, 2015
Assignee:
Octapharma AG
Inventors:
Andrea Neisser-Svae, Stefan Winge, Anna Mjärdestam
Abstract: The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.
Abstract: The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.
Abstract: A method for purification of complement Factor H from a complement Factor H containing source such as blood or blood plasma, in particular a caprylate precipitate of a Factor H containing source, which is e.g. obtained by addition of caprylate ions to fractions of blood or plasma, comprising the steps of: a) providing a Factor H containing source, in particular reconstitution of caprylate precipitate to provide a complement Factor H containing solution; b) performing a cation exchange chromatography in particular as first chromatographic step; c) performing an anion exchange chromatography; d) performing a hydroxyl apatite chromatography; e) followed by ultra/diafiltration to obtain a complement Factor H concentrate.
Type:
Grant
Filed:
October 13, 2011
Date of Patent:
August 19, 2014
Assignee:
Octapharma AG
Inventors:
Hubert Brandstaetter, Petra Schulz, Juergen Roemisch
Abstract: A method for stabilising a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa.
Abstract: A process of freeze drying of an essentially aqueous solution comprising at least one first step having a first temperature and pressure level (i.e. primary drying phase) and at least one second step having a second temperature and pressure level (i.e. secondary drying phase) following the first step, wherein in the secondary drying phase limited desorption energy input is applied.